COMMUNIQUÉS West-GlobeNewswire

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

24/10/2024 - 15:00

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune [...]

Philips and Medtronic advocacy partnership aims to help accelerate access to life-saving treatments

24/10/2024 - 15:00

October 24, 2024 Both companies also join the newly established World Stroke Organization Advocacy Coalition Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and [...]

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

24/10/2024 - 15:00

EDEN PRAIRIE, Minn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and [...]

Nephros Launches New HydraGuard 20” UltraFilter

24/10/2024 - 15:00

New Filter Targets Additional Industries and Water Quality Compliance SOUTH ORANGE, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH) Nephros, Inc., a leader in advanced filtration technology, is [...]

BioAge Labs to Present at Jefferies London Healthcare Conference

24/10/2024 - 15:00

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the [...]

Tomi Environmental Solutions, Inc. to Hold Conference Call to Discuss Third Quarter 2024 Financial Results on October 30, 2024

24/10/2024 - 14:46

FREDERICK, Md., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]

Chromocell Announces Amendment to Stock Repurchase Plan

24/10/2024 - 14:45

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, [...]

RedDress Announces ActiGraft Pro Added to WCA Formulary

24/10/2024 - 14:40

Chosen for List After Comprehensive Evaluation by Team of Wound Care Experts TEL AVIV, Israel and JACKSONVILLE, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RedDress ®, developers of the ActiGraft® Pro system, a personalized [...]

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

24/10/2024 - 14:30

SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe [...]

Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

24/10/2024 - 14:30

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third- [...]

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

24/10/2024 - 14:30

- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases, offering a potential [...]

CorMedix Inc. Announces New Data at ASN Kidney Week 2024

24/10/2024 - 14:30

Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs) BERKELEY HEIGHTS, N.J., [...]

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

24/10/2024 - 14:30

Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic [...]

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

24/10/2024 - 14:30

In addition to cognitive benefit, pepinemab is believed to preserve vascular integrity in brain, a key consideration to avoid toxicity in Alzheimer’s disease ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, [...]

Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil

24/10/2024 - 14:30

Developer Praises Intelligent Bio Solutions’ Innovative Drug Testing Solution for Improving Workplace Safety NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the " [...]

Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT

24/10/2024 - 14:04

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly specific on-target [...]

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

24/10/2024 - 14:01

Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectively Eight of [...]

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

24/10/2024 - 14:00

REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

24/10/2024 - 14:00

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent [...]